Richard is an alumnus of the University of Ottawa's SUNLAB.
Mitacs gratefully acknowledges Western Economic Diversification, the Atlantic Canada Opportunities Agency and the governments of Alberta, British Columbia, Manitoba, and New Brunswick for their support of Mitacs Elevate. In addition, select Elevate fellows are supported through Mitacs Accelerate and its funding partners.
Mitacs gratefully acknowledges the Government of Canada, the Networks of Centres of Excellence's Industrial Research and Development Internship program, Western Economic Diversification, the Atlantic Canada Opportunities Agency, Alberta Innovates Technology Futures and the governments of British Columbia, New Brunswick, Nova Scotia, Ontario, Quebec through Le Fonds de recherche du Québec - Nature et technologies, Manitoba, Saskatchewan and Newfoundland and Labrador through its Research and Development Corporation for their support of Mitacs Accelerate.
Mitacs gratefully acknowledges the Government of Canada, the Networks of Centres of Excellence's Industrial Research and Development Internship program, Western Economic Diversification, the Atlantic Canada Opportunities Agency, Alberta Innovates Technology Futures and the governments of British Columbia, New Brunswick, Nova Scotia, Ontario, Quebec through Le Fonds de recherche du Québec - Nature et technologies, Manitoba, Saskatchewan and Newfoundland and Labrador through its Research and Development Corporation for their support of Mitacs Accelerate.
When Actavis Specialty Pharmaceuticals Co. developed a new drug to treat uterine fibroids — benign tumors in a woman’s uterus — it partnered with Accelerate intern Bernice Tsoi to help create an economic model of the product. As a Health Research Methodology PhD student at McMaster University, conducting a thorough analysis of the drug’s costs and benefits was right up Bernice’s alley.
Chelation Partners’ approach to fighting antibiotic-resistant diseases is a novel one: cutting off their supply of iron. Without iron, bacteria have a tough time growing, and they’re more vulnerable to the effects of antibiotics. What’s more, Chelation Partners has discovered this tactic could also be applied to the fight against cancer. Cancer cells seem to be more sensitive to lower iron levels than other cells in the body, so reducing the availability of the metal might restrict the growth of cancer and boost the effectiveness of chemotherapy and radiation treatment.
Supported by Mitacs, the partnership between Trojan Technologies and Western University has grown considerably over the last four years. Since 2010, Trojan has invested a significant portion of its research budget to hire Mitacs interns, an amount that has been more than matched through Mitacs funding for a total of $1.5 million in R&D spending.
Currently, the company is building a three-year research program that will further expand their collaborations to include research on opaque fluids, as well as UV treatment of ballast water, waste water, and drinking water.
Teledyne DALSA is a Canadian manufacturer of specialized electronic imaging components with offices in Montreal. The company is a leading manufacturer of heat (infrared) sensors for use in satellites, surveillance and medical applications — fields which attract extensive research and development investment from both government and industry.
Researchers like Yang Yang, a Mitacs Elevate postdoctoral fellow in the Pharmaceutical Orthopaedic Research lab at the University of Alberta, are tackling the problem head-on by developing new treatments for the disease. In partnership with Osteo-Metabolix Pharmaceuticals Inc., Yang has created a new drug that does a better job of healing broken bones.
